Ernexa Therapeutics Inc Quick Ratio (ERNA) starting from the third quarter 2026 to third quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Ernexa Therapeutics Inc   (NASDAQ: ERNA)

Ernexa Therapeutics Inc 's Quick Ratio

ERNA's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Ernexa Therapeutics Inc 's Cash & cash equivalent grew by 10.88 % in the Q3 2026 sequentially, while Current Liabilities decreased, this led to improvement in Ernexa Therapeutics Inc 's Quick Ratio to 2.13, above Ernexa Therapeutics Inc average Quick Ratio.

Within Major Pharmaceutical Preparations industry 301 other companies have achieved higher Quick Ratio than Ernexa Therapeutics Inc in third quarter 2026. While Quick Ratio total ranking in the third quarter 2026 has deteriorated compared to the prior quarter from 598 to 1516.

Explain Quick Ratio?
How much Cash & cash equivalents ERNA´s has?
What are ERNA´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ERNA Quick Ratio (Sep 30 2026)
Q3		 (Jun 30 2026)
Q2		 (Mar 31 2026)
Q1		 (Dec 31 2025)
Q4		 (Sep 30 2025)
Q3
Y / Y Current Liabilities Change 34.88 % 20.46 % -66.88 % 13.99 % -80.53 %
Y / Y Cash & cash equivalent Change 82.97 % 16.52 % 378.47 % 8.96 % -28.54 %
Quick Ratio MRQ 2.13 1.71 2.65 0.61 1.57
ERNA's Total Ranking # 1516 # 598 # 1789 # 1115 #
Seq. Current Liabilities Change -10.85 % -15.19 % 11.05 % 60.63 % -20.38 %
Seq. Cash & cash equivalent Change 10.88 % -45.21 % 387.1 % -38.17 % -29.39 %



Quick Ratio third quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 302
Healthcare Sector # 528
Overall Market # 1516


Quick Ratio Statistics
High Average Low
6.77 1.27 0.18
(Mar 31 2022)   (Mar 31 2025)




Financial Statements
Ernexa Therapeutics Inc 's Current Liabilities $ 3 Millions Visit ERNA's Balance sheet
Ernexa Therapeutics Inc 's Cash & cash equivalent $ 6 Millions Visit ERNA's Balance sheet
Source of ERNA's Sales Visit ERNA's Sales by Geography


Cumulative Ernexa Therapeutics Inc 's Quick Ratio

ERNA's Quick Ratio for the trailling 12 Months

ERNA Quick Ratio

 (Sep 30 2026)
12 Months		 (Jun 30 2026)
12 Months		 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth -30.93 % -55.23 % -66.56 % -34.05 % -39.1 %
Y / Y Cash & cash equivalent TTM Growth 96.78 % 56.52 % 75.51 % -18.48 % -43.66 %
Quick Ratio TTM 1.79 1.67 1.68 0.62 0.63
Total Ranking TTM # 3857 # 2072 # 2976 # 3123 #
Seq. Current Liabilities TTM Growth 5.91 % 4.55 % -38.95 % 2.18 % -31.36 %
Seq. Cash & cash equivalent TTM Growth 13.21 % 3.87 % 65.02 % 1.41 % -9.95 %

Quick ratio ranking by company, industry and sector >> Back to ERNA Financial Strength Comparisons >> Go to Compare ERNA Quick Ratio to its Competitors

On the trailing twelve months basis ERNA Cash & cash equivalent soared by 82.97 % in Q3 2026 year on year, faster than Current Liabilities, this led to increase in in Ernexa Therapeutics Inc 's Quick Ratio to 1.79, above ERNA average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 433 other companies have achieved higher Quick Ratio than Ernexa Therapeutics Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2026 from 2072 to 3857.

Explain Quick Ratio?
How much Cash & cash equivalents ERNA´s has?
What are ERNA´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 434
Healthcare Sector # 886
Within the Market # 3857


trailing twelve months Quick Ratio Statistics
High Average Low
5.97 1.21 0.32
(Mar 31 2022)   (Mar 31 2025)




Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within Major Pharmaceutical Preparations Industry Quick RatioSep 30 2026 MRQ Cash & cash equivalentSep 30 2026 MRQ Current Liabilities
Summit Therapeutics Inc   5.71 $ 629.899  Millions$ 110.226  Millions
Nurix Therapeutics Inc   5.51 $ 720.458  Millions$ 130.742  Millions
United Therapeutics Corporation  5.51 $ 3,439.800  Millions$ 624.300  Millions
Immuneering Corporation  5.45 $ 58.776  Millions$ 10.791  Millions
Aquestive Therapeutics Inc   5.22 $ 90.349  Millions$ 17.299  Millions
Rani Therapeutics Holdings Inc   4.91 $ 45.288  Millions$ 9.223  Millions
Abeona Therapeutics Inc   4.87 $ 134.941  Millions$ 27.707  Millions
Shattuck Labs Inc   4.84 $ 61.758  Millions$ 12.758  Millions
Entrada Therapeutics Inc   4.34 $ 112.302  Millions$ 25.863  Millions
Gyre Therapeutics Inc   4.34 $ 86.190  Millions$ 19.874  Millions
Foghorn Therapeutics Inc   4.19 $ 156.222  Millions$ 37.315  Millions
Revelation Biosciences Inc   3.92 $ 9.122  Millions$ 2.328  Millions
Tonix Pharmaceuticals Holding Corp   3.87 $ 162.793  Millions$ 42.026  Millions
Lyell Immunopharma Inc   3.83 $ 177.106  Millions$ 46.271  Millions
Rapport Therapeutics Inc   3.68 $ 74.754  Millions$ 20.302  Millions
Seaport Therapeutics Inc   3.60 $ 61.552  Millions$ 17.106  Millions
Cytokinetics Incorporated  3.20 $ 1,130.021  Millions$ 353.419  Millions
Elicio Therapeutics Inc   3.11 $ 30.900  Millions$ 9.930  Millions
Harmony Biosciences Holdings inc   3.02 $ 771.138  Millions$ 254.981  Millions
Phio Pharmaceuticals Corp  2.96 $ 10.609  Millions$ 3.583  Millions
Zevra Therapeutics Inc   2.95 $ 122.148  Millions$ 41.369  Millions
Pyxis Oncology Inc   2.79 $ 55.572  Millions$ 19.942  Millions
Zenas Biopharma Inc   2.78 $ 177.778  Millions$ 64.043  Millions
Ptc Therapeutics inc   2.74 $ 2,127.918  Millions$ 776.076  Millions
Turn Therapeutics Inc   2.71 $ 9.433  Millions$ 3.479  Millions
Beone Medicines Ltd   2.67 $ 5,955.905  Millions$ 2,233.923  Millions
Biohaven Ltd   2.57 $ 161.125  Millions$ 62.767  Millions
Ironwood Pharmaceuticals inc   2.49 $ 86.376  Millions$ 34.733  Millions
Tg Therapeutics Inc   2.43 $ 632.004  Millions$ 260.526  Millions
Adc Therapeutics Sa  2.42 $ 189.204  Millions$ 78.125  Millions

Date modified: 2026-11-07T06:36:30+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.